Revenue: As of FY2025 Q3, the actual value is USD 301.98 K.EPS: As of FY2025 Q3, the actual value is USD -0.014.EBIT: As of FY2025 Q3, the actual value is USD -347.18 K.<h3>Segment Revenue</h3><ul><li>Direct Sales: Revenue was $13,735 for the three months ended September 30, 2025, a decrease of 87% from $102,370 in the same period of 2024.</li><li>Pharmacy: Revenue was $16,933 for the three months ended September 30, 2025, a decrease of 94% from $266,664 in the same period of 2024.</li><li>Hotel: Revenue was $135,548 for the three months ended September 30, 2025, a decrease of 29% from $190,861 in the same period of 2024.</li><li>Manufacture and Sale: Revenue was $135,763 for the three months ended September 30, 2025, a decrease of 64% from $376,511 in the same period of 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended September 30, 2025, was $340,461, compared to a net loss of $546,186 for the same period in 2024, a decrease of 38%.</li><li>Operating Costs and Expenses: Total operating costs and expenses were $649,188 for the three months ended September 30, 2025, compared to $1,538,989 for the same period in 2024, a decrease of 57%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $1,772,076, compared to $548,130 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Customer Concentration: During the three months ended September 30, 2025, one customer accounted for 38% of total revenue.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to gain positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products. Additionally, it aims to raise cash through loans from related parties and potential equity offerings.</li><li>Non-Core Business: The company intends to explore opportunities in the healthcare market in China, including expanding its product line, acquiring additional pharmacies, and potentially operating nursing homes and clinics.</li></ul>

AiXin Life International, Inc. | 10-Q: FY2025 Q3 Revenue: USD 301.98 K